Invenio Imaging, Inc., a leader in intraoperative fresh tissue imaging and artificial intelligence, today announced that it has entered into a research collaboration agreement with the Lung Cancer Initiative at Johnson & Johnson* to develop and validate the NIO® Lung Cancer Reveal image analysis algorithm to assist physicians in the evaluation of bronchoscopic lung biopsies.
The NIO® Laser Imaging Systems allows rapid imaging of fresh tissue biopsies with subcellular resolution in the procedure room with minimal preparation while preserving the sample for additional downstream pathology analysis. “In this important clinical study, we will develop a novel image analysis algorithm based on machine learning to provide physicians with real-time feedback determining whether a biopsy sample contains cancer”, says Chris Freudiger, PhD, Co-Founder and CTO of Invenio Imaging.
“We are excited to undertake this ambitious clinical study in collaboration with the Lung Cancer Initiative”, says Jay Trautman, PhD, Co-Founder and CEO of Invenio Imaging.
NIO® Lung Cancer Reveal has not been cleared by the Food and Drug Administration for clinical use in the United States.
